Venture Valuation recently published an article in Nature Biotechnology 32, 617–619, (2014) based on data from its Biotechgate deals database looking at the difference between big pharma and SMEs in the upfront payments and number of deals. Read more here (Nature Biotechnology) To get access to Biotechgate, please contact us here. Source: Nature Biotechnology, 32, … Continue reading The premium of a big pharma license deal
Marketing alliances between well-known brand names and consumer products have long been a tradition for example Michael Jackson and Pepsi or George Clooney and Nespresso. Soccer clubs are also dependent on sponsor income and are working with many different industries like telecoms, airlines and insurances. Now prestigious Manchester United (Man U) has signed a marketing … Continue reading Soccer and Pharma/BIOtech
Orphan drugs have been en vogue for a while. However, in the last quarter there has been a record financing that has put drugs for small patient populations on the map even more. In Q1 2014, over 60% of the financing in European Biotech has gone to companies that have a lead orphan drug product. … Continue reading Is Orphan saving Biotech?
Are you wondering what investors still have money and are investing? At Biotechgate we are tracking all financing of investors and we also run a global database of what investors are looking for. As an example, the following investors have made investments into European Health Care companies in Q1 2014: AT NewTec, Germany Boehringer Ingelheim … Continue reading Who is investing and who is not?
With the announcement of the portfolio transformation of Novartis this month, we believe this will have a positive impact on the biotech industry. The company will focus on Pharmaceuticals, Eye Care and Generics. The diversification strategy of former CEO and Chairman Daniel Vasella has been axed by the new leadership of Novartis. Key components of … Continue reading What is the impact of Novartis transformation on biotech industry?
Even with the public biotech was just at an all time high, VCs in the US also have difficulties convincing LPs (Limited Partners) to make investment in their funds. At a recent panel discussion led by Venture Valuation at the RESI (redefining early stage investment) conference in Boston, VCs offered an insight into their perspective … Continue reading Early stage VC funding in the US more difficult than ever
Does it make sense for a life science fundraising executive in Europe to look internationally for early-stage funding? Should U.S. based firms look at investors in Europe and Asia? As the famous folk singer Bob Dylan sang “the times they are a changing” and the answer is yes! To someone looking to fund a … Continue reading Global, Early-Stage Investors in Emerging Life Science Companies
The recent acquisition of Forest Laboratories Inc. by Actavis for USD 25bn shows the trend of generic producers to move into the innovative drug space. With fewer blockbusters on the market, companies focused on generics will need to move into innovative therapeutics. The acquisition of Forest Laboratories Inc. by Actavis is a clear sign where … Continue reading Licensing demand for biotech products will increase
The meaning of a “discount rate” is best understood by making a parallel with the interest rate you get from the bank on your savings account. While the interest rate is a % you use to calculate what 100 USD or EUR on your account will become after a number of years, the discount rate … Continue reading How do you determine the discount rate you need to calculate the current value of a company that hasn’t generated revenues yet?
For Life Sciences companies it has never been easy selecting a location for HQs, shared services centers, manufacturing or R+D operations in Europe. A huge variety of factors must be taken into consideration. Venture Valuation, together with KPMG has analyzed the key decision factors relevant to site selection in Europe. Click here to read or … Continue reading Site Selection for Life Sciences Companies 2013
